Satellos Bioscience Inc. has experienced notable price fluctuations this week as it continues to develop treatments for Duchenne muscular dystrophy.
This week, Satellos Bioscience Inc. (MSCL.TO) saw a decline of 3.80%, closing at C$12.14, down 4.48% on Thursday. However, the stock has gained 51.75% over the past month as the company advances its clinical trials and aims to establish a presence on the Nasdaq.
Investor takeaway: While recent price movements may concern investors, the company's ongoing developments, including FDA designations and clinical trial progress, could lay the groundwork for future growth.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$275.81M
52W high
$18.98
52W low
$7.08
1W change
-5.35%
Beta
1.17
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 35.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+35.1% Upside
Current Price
C$13.08
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
56.6%
Annualized
90-Day Vol
74.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$15.64
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$13.88 | C$11.42 โ C$16.87 |
| 60 trading days | C$14.73 | C$11.18 โ C$19.42 |
| 90 trading days | C$15.64 | C$11.15 โ C$21.93 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience's Stock Performance Highlights
With a market cap of approximately C$264.76 million and a 52-week range of C$6.36 to C$18.98, the stock has shown both volatility and potential for growth.
Bull case
Satellos's recent FDA Fast Track designation for its treatment SAT-3247 is a significant milestone that could speed up its path to market. The promising results from the Phase 1b trial suggest the drug's potential effectiveness, which may attract investor interest and support stock appreciation.
Bear case
Despite these positive developments, the company has a negative return on equity, and its lack of profitability may deter some investors. Additionally, the recent price drop could indicate market volatility and uncertainty about the company's future performance.
Weekly Price Action
Satellos Bioscience Inc. (MSCL.TO) closed at C$12.14 on Thursday, reflecting a 4.48% decline for the day and a 3.80% decrease over the week. Despite this drop, the stock has risen significantly over the past month, gaining 51.75%. This fluctuation may be linked to ongoing developments in the company's clinical trials and market responses.
Recent Company Developments
Advertisement
There were no major company news releases this week. However, notable past developments include the FDA granting Fast Track designation for SAT-3247, aimed at treating Duchenne muscular dystrophy. This designation is intended to expedite the development and review process for drugs that address serious conditions and fill an unmet medical need. Earlier this year, the company also raised US$57.2 million in equity financing and initiated Phase 2 trials for SAT-3247.
Technical Picture
From a technical standpoint, Satellos is currently trading above its 50-day moving average of C$9.76, representing a 24.3% increase, and its 200-day moving average of C$10.40, which is 16.7% higher than the current price. The stock has a beta of 1.17, indicating it is slightly more volatile than the overall market. The 52-week range of the stock is C$6.36 to C$18.98, showing it is currently trading at approximately 46% of its 52-week high. The latest trading volume was 32,140 shares, slightly below the 20-day average volume of 35,468 shares.
Insider Activity
No recent insider activity has been reported for Satellos Bioscience Inc., which may interest investors monitoring insider buying or selling as an indicator of confidence in the company's future.
Price Action Summary
As of the latest close, Satellos Bioscience Inc. is trading at C$12.14, down 4.48% for the day. Investors should closely monitor the stock's performance, especially in light of the company's ongoing clinical trials and potential market developments.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
